ABVC BioPharma has received approval from the Science Park Administration in Taiwan to establish a pilot Good Manufacturing Practise (GMP) facility. This facility will be dedicated to producing Vitargus®, an innovative product used in retinal detachment surgery.
In addition to production, ABVC BioPharma will focus on refining their manufacturing processes for optimal efficiency. The joint effort between ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation focuses on the enhancement of manufacturing processes for Vitargus®.
Vitargus®, a cutting-edge Vitreous Substitute, represents the first biodegradable hydrogel product intended for use in retinal detachment surgery. Having successfully concluded a feasibility study in Australia, Vitargus® received approval from the Australian Therapeutic Goods Administration (TGA) to proceed with the next phase of trials.
The focus on enhancing the facility's infrastructure is to yield substantial reductions in ongoing trial expenses, optimise production processes, kerbing costs linked to outsourcing to external Contract Research Organisations (CROs), and ensuring heightened operational efficiency.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!